Free functional muscle transfer failure and thrombophilic gene mutation as a potential risk factor: A case report

Microsurgery

Volumn 27, Issue 2, 2007, Pages 88-90

  Vekris, Marios D ^a   Ovrenovits, Maria ^b   Dova, Lefkothea ^b   Beris, Alexandros E ^a   Soucacos, Panayiotis N ^c   Kolaitis, Nikolaos ^b   Vartholomatos, George ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD CLOT; BRACHIAL PLEXUS; CASE REPORT; CHRONIC GRAFT REJECTION; DELAYED GRAFT FUNCTION; DISEASE SEVERITY; FOREARM; GENE MUTATION; GRAFT DYSFUNCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; MICROSURGERY; MUSCLE TRANSPLANTATION; PARALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; SURGEON; SURGICAL TECHNIQUE; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; BRACHIAL PLEXUS; FACTOR V; FOREARM INJURIES; GENETIC MARKERS; GRAFT SURVIVAL; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUSCLE, SKELETAL; MUTATION; POSTOPERATIVE COMPLICATIONS; SURGICAL FLAPS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 33947172574     PISSN: 07381085     EISSN: 10982752     Source Type: Journal    
DOI: 10.1002/micr.20312     Document Type: Article

References (14)

1. Terzis JK, Vekris MD, Soucacos PN. Outcomes of brachial plexus reconstruction in 204 patients with devastating paralysis. Plast Reconstr Surg 1999;104:1221-1240.
2. Terzis JK, Vekris MD, Soucacos PN. Brachial plexus root avulsions. World J Surg 2001;25:1049-1061.
3. Vekris MD, Soucacos PN. Post-traumatic brachial plexus paralysis: Current management of reconstruction. Curr Orthop 2001;15:76-83.
4. Soucacos PN, Beris A, Xenakis T, Malizos K, Vekris MD. Open type IIIb and IIIc fractures treated by an orthopaedic microsurgical team. Clin Orthop Relat Res 1995;314:59-66.
5. Wuthrich RP, Cicvara-Muzar S, Booy C, Maly FE. Heterozygosity for the factor V Leiden (G1691) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation 2005;72:549-550.
6. Hocher B, Slowinski T, Vetter B, Fritsche L, Bachert D, Kulozik A, Neumayer HH. Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients. Thromb Haemost 2002; 87:194-198.
7. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: Effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000;83:577-582.
8. Mingozzi F, Legnani C, Lunghi B, Scanavini D, Castoldi E, Palareti G, Marchetti G, Bernardi F. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers. Thromb Haemost 2003;89:983-989.
9. Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Finazzi G, Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999;94:3062-3066.
10. Alhenc-Gelas M, Arnaud E, Nicaud V, Aubry ML, Fiessinger JN, Aiach M, Emmerich J. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999;81:506-510.
11. Luddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000;83:204-208.
12. Boushey CJ, Beresfor SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
13. Den heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
14. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-176.